{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:09:47Z","timestamp":1784592587058,"version":"3.55.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lfs.2024.123186","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T05:52:12Z","timestamp":1730267532000},"page":"123186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies"],"prefix":"10.1016","volume":"358","author":[{"given":"Abinesh","family":"R.S.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Trideva","family":"Sastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"G.S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"A.R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamuralidhara","family":"V.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.123186_bb0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcf.2007.02.002","article-title":"Genetic screening for cystic fibrosis: an overview of the science and the economics","volume":"6","author":"Brice","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.lfs.2024.123186_bb0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0025-7125(05)70243-1","article-title":"Genotype-phenotype relationships in cystic fibrosis","volume":"84","author":"Mickle","year":"2000","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.lfs.2024.123186_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1155\/2015\/921712","article-title":"A new era of personalized medicine for cystic fibrosis \u2013 at last!","volume":"22","author":"Quon","year":"2015","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.lfs.2024.123186_bb0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.fertnstert.2018.05.006","article-title":"Personalized medicine: motivation, challenges and progress","volume":"109","author":"Goetz","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123186_bb0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","article-title":"Pharmacogenomics: driving personalized medicine","volume":"75","author":"Sadee","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/EBC20180038","article-title":"Understanding biochemistry: structure and function of nucleic acids","volume":"63","author":"Minchin","year":"2019","journal-title":"Essays Biochem."},{"key":"10.1016\/j.lfs.2024.123186_bb0035","unstructured":"CF genetics: the basics|Cystic Fibrosis Foundation n.d. https:\/\/www.cff.org\/intro-cf\/cf-genetics-basics (accessed May 11, 2024)."},{"key":"10.1016\/j.lfs.2024.123186_bb0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.lfs.2024.123186_bb0045","unstructured":"A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis|New England Journal of Medicine n.d. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJM199004263221704 (accessed May 11, 2024)."},{"key":"10.1016\/j.lfs.2024.123186_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001868","article-title":"The \u0394F508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs","volume":"3","author":"Ostedgaard","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0055","doi-asserted-by":"crossref","first-page":"00746","DOI":"10.1183\/23120541.00746-2023","article-title":"Cystic fibrosis airway inflammation enables elexacaftor\/tezacaftor\/ivacaftor-mediated rescue of N1303K CFTR mutation","volume":"10","author":"Gentzsch","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.lfs.2024.123186_bb0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.lfs.2024.123186_bb0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.lfs.2024.123186_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0272-5231(05)70092-7","article-title":"Clinical implications of cystic fibrosis transmembrane conductance regulator mutations","volume":"19","author":"Mickle","year":"1998","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006648","article-title":"Protein ensembles link genotype to phenotype","volume":"15","author":"Nussinov","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.lfs.2024.123186_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000029497","article-title":"Genotype and phenotype in cystic fibrosis","volume":"67","author":"Zielenski","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.lfs.2024.123186_bb0085","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM199011293232203","article-title":"The relation between genotype and phenotype in cystic fibrosis \u2014 analysis of the Most common mutation (\u0394F508)","volume":"323","author":"Eitan","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0090","first-page":"1178","article-title":"Genetic determination of exocrine pancreatic function in cystic fibrosis","volume":"50","author":"Kristidis","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.lfs.2024.123186_bb0095","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20212006","article-title":"Molecular mechanisms of cystic fibrosis \u2013 how mutations lead to misfunction and guide therapy","volume":"42","author":"Farinha","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.lfs.2024.123186_bb0100","series-title":"Correlation Between Genotype and Phenotype in Patients With Cystic Fibrosis","author":"Hamosh","year":"1993"},{"key":"10.1016\/j.lfs.2024.123186_bb0105","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199506013322204","article-title":"Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens","volume":"332","author":"Miguel","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0110","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.1992.03480130110034","article-title":"Congenital bilateral absence of the vas deferens: a primarily genital form of cystic fibrosis","volume":"267","author":"Anguiano","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2024.123186_bb0115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1542\/peds.30.3.389","article-title":"Nasal polyposis in patients with cystic fibrosis","volume":"30","author":"Shwachman","year":"1962","journal-title":"Pediatrics"},{"key":"10.1016\/j.lfs.2024.123186_bb0120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jama.1956.02960450028007","article-title":"Fibrocystic disease of the pancreas, a generalized disease of exocrine glands","volume":"160","author":"Sant\u2019Agnese PA","year":"1956","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2024.123186_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM196807112790203","article-title":"Reproductive failure in males with cystic fibrosis","volume":"279","author":"Elvin","year":"1968","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(93)91885-P","article-title":"Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation","volume":"342","author":"Augarten","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2024.123186_bb0135","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Edward","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/HUMREP\/11.3.513","article-title":"Cystic fibrosis mutation screening in healthy men with reduced sperm quality","volume":"11","author":"van der Ven","year":"1996","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123186_bb0145","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.284.14.1814","article-title":"Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population","volume":"284","author":"Wang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2024.123186_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1096-8628(20001211)95:4<361::AID-AJMG12>3.0.CO;2-K","article-title":"Frequency and clinical significance of the S1235R mutation in the cystic fibrosis transmembrane conductance regulator gene: Results from a collaborative study","volume":"95","author":"Monaghan","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.lfs.2024.123186_bb0155","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0025-7125(05)70243-1","article-title":"Genotype-phenotype relationships in cystic fibrosis","volume":"84","author":"Mickle","year":"2000","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.lfs.2024.123186_bb0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ajmg.a.10886","article-title":"A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype\u2013phenotype manifestations","volume":"116A","author":"Kulczycki","year":"2003","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.lfs.2024.123186_bb0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/21548331.2001.11444081","article-title":"New approaches to cystic fibrosis","volume":"36","author":"Moss","year":"2001","journal-title":"Hosp. Pract."},{"key":"10.1016\/j.lfs.2024.123186_bb0170","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1542\/peds.107.2.280","article-title":"Comprehensive mutation screening in a cystic fibrosis center","volume":"107","author":"Wine","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.lfs.2024.123186_bb0175","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/jcm10245821","article-title":"Genetic modifying factors of cystic fibrosis phenotype: a challenge for modern medicine","volume":"10","author":"Butnariu","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0180","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms21113903","article-title":"Gene therapy for cystic fibrosis: progress and challenges of genome editing","volume":"21","author":"Maule","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0044-1785234","article-title":"CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications","volume":"11","author":"Kolanu","year":"2024","journal-title":"Glob. Med. Genet."},{"key":"10.1016\/j.lfs.2024.123186_bb0190","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1172\/JCI118573","article-title":"Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis","volume":"97","author":"Zabner","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.123186_bb0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1172\/JCI7935","article-title":"Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus","volume":"104","author":"Harvey","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.123186_bb0200","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/sj.gt.3301212","article-title":"Repeat administration of DNA\/liposomes to the nasal epithelium of patients with cystic fibrosis","volume":"7","author":"Hyde","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0205","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(98)06532-5","article-title":"Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial","volume":"353","author":"Alton","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2024.123186_bb0210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2024.123186_bb0215","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1164\/ajrccm.162.5.9909009","article-title":"Cystic fibrosis sputum","volume":"162","author":"Sanders","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0220","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.gt.3301525","article-title":"Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium","volume":"8","author":"Ferrari","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0225","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.lfs.2024.123186_bb0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2014.01.007","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"178","author":"Suk","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2024.123186_bb0235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ymthe.2004.11.015","article-title":"Structure\/property studies of polymeric gene delivery using a library of poly(\u03b2-amino esters)","volume":"11","author":"Anderson","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0240","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0250","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123186_bb0260","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1073\/pnas.0401933101","article-title":"Reversal of cystic fibrosis phenotype in a cultured \u0394508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion","volume":"101","author":"Zamecnik","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0265","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of Ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0270","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.coph.2017.10.006","article-title":"Genetic therapies for cystic fibrosis lung disease","volume":"34","author":"Hart","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123186_bb0275","doi-asserted-by":"crossref","unstructured":"Cooney AL, Abou Alaiwa MH, Shah VS, Bouzek DC, Stroik MR, Powers LS, et al. Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight n.d.;1:e88730. doi:https:\/\/doi.org\/10.1172\/jci.insight.88730.","DOI":"10.1172\/jci.insight.88730"},{"key":"10.1016\/j.lfs.2024.123186_bb0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2024.123186_bb0285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature25786","article-title":"Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor","volume":"555","author":"Zacharias","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123186_bb0290","doi-asserted-by":"crossref","first-page":"719","DOI":"10.5966\/sctm.2012-0056","article-title":"Isolation and in vitro characterization of basal and submucosal gland duct stem\/progenitor cells from human proximal airways","volume":"1","author":"Hegab","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0295","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/stem.1440","article-title":"Regulation of trachebronchial tissue-specific stem cell POOL size","volume":"31","author":"Ghosh","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.lfs.2024.123186_bb0300","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A revised airway epithelial hierarchy includes CFTR-expressing ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123186_bb0305","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","article-title":"A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte","volume":"560","author":"Plasschaert","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123186_bb0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.200502-309OC","article-title":"Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow\u2013derived cells","volume":"173","author":"Loi","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0315","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13287-018-0911-4","article-title":"Epithelial disruption: a new paradigm enabling human airway stem cell transplantation","volume":"9","author":"Farrow","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.lfs.2024.123186_bb0320","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1164\/rccm.201506-1193LE","article-title":"A phase I\/IIa safety and efficacy study of nebulized liposome-mediated gene therapy for cystic fibrosis supports a multidose trial","volume":"192","author":"Alton","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0325","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0330","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/hum.2015.144","article-title":"Transfer of the cystic fibrosis transmembrane conductance regulator to human cystic fibrosis cells mediated by extracellular vesicles","volume":"27","author":"Vituret","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0335","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/ppul.23543","article-title":"Genetic medicines for CF: hype versus reality","volume":"51","author":"Alton","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.lfs.2024.123186_bb0340","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2024.123186_bb0345","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/acs.nanolett.5b03528","article-title":"An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo","volume":"15","author":"Li","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.lfs.2024.123186_bb0350","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.lfs.2024.123186_bb0355","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","article-title":"Refining strategies to translate genome editing to the clinic","volume":"23","author":"Cornu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0360","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00439-016-1693-3","article-title":"Impact of gene editing on the study of cystic fibrosis","volume":"135","author":"Harrison","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.lfs.2024.123186_bb0365","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stemcr.2015.02.005","article-title":"Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells","volume":"4","author":"Crane","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.lfs.2024.123186_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161072","article-title":"Targeted integration of a super-exon into the CFTR locus leads to functional correction of a cystic fibrosis cell line model","volume":"11","author":"Bednarski","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123186_bb0375","doi-asserted-by":"crossref","first-page":"19934","DOI":"10.1073\/pnas.0900946106","article-title":"Intronic enhancers coordinate epithelial-specific looping of the active CFTR locus","volume":"106","author":"Ott","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lfs.2024.123186_bb0385","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12864-017-3746-y","article-title":"GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases","volume":"18","author":"Zhu","year":"2017","journal-title":"BMC Genomics"},{"key":"10.1016\/j.lfs.2024.123186_bb0390","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR\u2013Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lfs.2024.123186_bb0395","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt.3241","article-title":"In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency","volume":"33","author":"Mahiny","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2024.123186_bb0400","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1038\/ncomms7952","article-title":"Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium","volume":"6","author":"McNeer","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2024.123186_bb0405","first-page":"5","article-title":"Homology requirements for efficient, footprintless gene editing at the CFTR locus in human iPSCs with helper-dependent adenoviral vectors","author":"Palmer","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.lfs.2024.123186_bb0410","article-title":"An efficient system for selectively altering genetic information within mRNAs","volume":"44","author":"Montiel-Gonz\u00e1lez","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2024.123186_bb0415","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1378\/chest.13-0693","article-title":"Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations","volume":"144","author":"Shoki","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2024.123186_bb0420","first-page":"10","article-title":"Metabolomic biomarkers to predict and diagnose cystic fibrosis pulmonary exacerbations: a systematic Review","author":"Nguyen","year":"2022","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.lfs.2024.123186_bb0425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2466-14-150","article-title":"Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis","volume":"14","author":"Gir\u00f3n-Moreno","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0430","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thoraxjnl-2012-202538","article-title":"Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation","volume":"68","author":"Horsley","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2024.123186_bb0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00216-021-03813-7","article-title":"Data analysis methods for defining biomarkers from omics data","volume":"414","author":"Li","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.lfs.2024.123186_bb0440","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/gm209","article-title":"Protein biomarkers in cystic fibrosis research: where next?","volume":"2","author":"Pattison","year":"2010","journal-title":"Genome Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0445","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00018-021-04094-0","article-title":"Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis","volume":"79","author":"Zheng","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0450","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: new tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0455","first-page":"1553","article-title":"Genetic factors in drug metabolism","volume":"77","author":"Belle","year":"2008","journal-title":"Afp"},{"key":"10.1016\/j.lfs.2024.123186_bb0460","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40262-020-00932-9","article-title":"Pharmacokinetics in patients with cystic fibrosis: a systematic review of data published between 1999 and 2019","volume":"59","author":"De Sutter","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2024.123186_bb0465","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-010-0914-2","article-title":"Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients","volume":"67","author":"Berge","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123186_bb0470","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3184\/003685014X13926384776999c","article-title":"Molecular pharmacology from DNA to drug discovery","volume":"97","author":"Review","year":"2014","journal-title":"Sci. Prog."},{"key":"10.1016\/j.lfs.2024.123186_bb0475","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","article-title":"An update on CFTR modulators as new therapies for cystic fibrosis","volume":"24","author":"King","year":"2022","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.lfs.2024.123186_bb0480","series-title":"Anion Channels and Transporters","first-page":"219","article-title":"CFTR modulators: from mechanism to targeted therapeutics","author":"Yeh","year":"2024"},{"key":"10.1016\/j.lfs.2024.123186_bb0485","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009779","article-title":"Antibiotic and anti-inflammatory therapies for cystic fibrosis","volume":"3","author":"Chmiel","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0490","series-title":"Treatment of Cystic Fibrosis and Other Rare Lung Diseases","first-page":"139","article-title":"Anti-inflammatory therapies for cystic fibrosis","author":"Dasenbrook","year":"2017"},{"key":"10.1016\/j.lfs.2024.123186_bb0495","first-page":"12","article-title":"Editorial: novel anti-inflammatory approaches for cystic fibrosis lung disease: identification of molecular targets and design of innovative therapies","author":"Ribeiro","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123186_bb0500","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1183\/09059180.00008512","article-title":"Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation","volume":"22","author":"Sermet-Gaudelus","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0505","article-title":"Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis","volume":"2018","author":"Southern","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0510","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lfs.2024.123186_bb0515","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0520","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123186_bb0525","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/pro.480","article-title":"Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis","volume":"19","author":"Wang","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0530","doi-asserted-by":"crossref","first-page":"28463","DOI":"10.1074\/jbc.271.45.28463","article-title":"ATPase activity of the cystic fibrosis transmembrane conductance regulator *","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.123186_bb0535","first-page":"L1117","article-title":"Rescue of \u0394F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.lfs.2024.123186_bb0540","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0545","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009761","article-title":"Cystic fibrosis transmembrane regulator correctors and potentiators","volume":"3","author":"Rowe","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0550","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03060","article-title":"A faux 3\u2032-UTR promotes aberrant termination and triggers nonsense- mediated mRNA decay","volume":"432","author":"Amrani","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123186_bb0555","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123186_bb0560","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations","volume":"52","author":"Nudelman","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123186_bb0565","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0570","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by Ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.lfs.2024.123186_bb0575","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.lfs.2024.123186_bb0585","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2024.123186_bb0590","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1159\/000265129","article-title":"Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease","volume":"29","author":"Leier","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2024.123186_bb0595","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2024.123186_bb0600","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1113\/jphysiol.2012.240861","article-title":"Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?","volume":"591","author":"Hobbs","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.lfs.2024.123186_bb0605","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/20734735.021014","article-title":"Inhaled therapy in cystic fibrosis: agents, devices and regimens","volume":"11","author":"Agent","year":"2015","journal-title":"Breathe (Sheff.)"},{"key":"10.1016\/j.lfs.2024.123186_bb0610","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics10050486","article-title":"Treatment of pulmonary disease of cystic fibrosis: a comprehensive review","volume":"10","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lfs.2024.123186_bb0615","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial Sodium Channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123186_bb0620","first-page":"24","article-title":"The epithelial sodium channel-an underestimated drug target","author":"R","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0625","doi-asserted-by":"crossref","first-page":"00447","DOI":"10.1183\/23120541.00447-2020","article-title":"First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers","volume":"7","author":"Mackie","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.lfs.2024.123186_bb0630","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0635","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1513\/AnnalsATS.201812-863OT","article-title":"Developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities","volume":"16","author":"Nichols","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.lfs.2024.123186_bb0640","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/antibiotics12030484","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","volume":"12","author":"Li","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.lfs.2024.123186_bb0645","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/ijms18051062","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0650","article-title":"Dornase alfa for cystic fibrosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0655","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12931-017-0578-x","article-title":"Lung function imaging methods in cystic fibrosis pulmonary disease","volume":"18","author":"Ko\u0142odziej","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2024.123186_bb0660","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12931-017-0578-x","article-title":"Lung function imaging methods in cystic fibrosis pulmonary disease","volume":"18","author":"Ko\u0142odziej","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2024.123186_bb0665","first-page":"31","article-title":"State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the \u201ciMAging managEment of cySTic fibROsis\u201d (MAESTRO) consortium","author":"Ciet","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0670","series-title":"MRI of the Lung","first-page":"277","article-title":"Magnetic resonance imaging of the lung: cystic fibrosis","author":"Nagle","year":"2018"},{"key":"10.1016\/j.lfs.2024.123186_bb0675","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/cancers14071654","article-title":"Using quantitative imaging for personalized medicine in pancreatic cancer: a review of radiomics and deep learning applications","volume":"14","author":"Preuss","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.123186_bb0680","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/AJR.16.17462","article-title":"Multisystem imaging findings of cystic fibrosis in adults: recognizing typical and atypical patterns of disease","volume":"209","author":"Averill","year":"2017","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.lfs.2024.123186_bb0685","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00247-020-04706-0","article-title":"Computed tomography in cystic fibrosis lung disease: a focus on radiation exposure","volume":"51","author":"Joyce","year":"2021","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.lfs.2024.123186_bb0690","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00247-022-05522-4","article-title":"Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives","volume":"53","author":"Ciet","year":"2023","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.lfs.2024.123186_bb0700","unstructured":"SciELO - Brasil - Nursing interventions in monitoring the adolescent with Cystic Fibrosis: a literature review Nursing interventions in monitoring the adolescent with Cystic Fibrosis: a literature review n.d. https:\/\/www.scielo.br\/j\/rlae\/a\/tmwS8NPfbc8Fc5pyLxF8JDj\/?lang=en (accessed May 11, 2024)."},{"key":"10.1016\/j.lfs.2024.123186_bb0705","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.908230","article-title":"The impact of air pollution on the course of cystic fibrosis: a review","volume":"13","author":"Blayac","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2024.123186_bb0715","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/nu15030479","article-title":"Nutritional care in children with cystic fibrosis","volume":"15","author":"Mariotti Zani","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2024.123186_bb0720","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/17476348.2022.2090928","article-title":"Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies","volume":"16","author":"Oates","year":"2022","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0725","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12866-023-02788-y","article-title":"Resilience and stability of the CF- intestinal and respiratory microbiome during nutritional and exercise intervention","volume":"23","author":"Knoll","year":"2023","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.lfs.2024.123186_bb0730","article-title":"Physical activity and exercise training in cystic fibrosis","volume":"2022","author":"Radtke","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0735","unstructured":"Challenges with optimizing nutrition in cystic fibrosis: Expert Rev. Respir. Med.: Vol 13, No 6 n.d. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17476348.2019.1614917\\ (accessed May 11, 2024)."},{"key":"10.1016\/j.lfs.2024.123186_bb0740","doi-asserted-by":"crossref","unstructured":"Nutrients|free full-text|nutrition in cystic fibrosis&mdash;some notes on the fat recommendations n.d. https:\/\/www.mdpi.com\/2072-6643\/14\/4\/853 (accessed May 11, 2024).","DOI":"10.3390\/nu14040853"},{"key":"10.1016\/j.lfs.2024.123186_bb0745","article-title":"Pancreatic enzyme replacement therapy for people with cystic fibrosis","volume":"2020","author":"Somaraju","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0750","doi-asserted-by":"crossref","first-page":"684","DOI":"10.17235\/reed.2017.4951\/2017","article-title":"Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption","volume":"109","author":"Calvo-Lerma","year":"2017","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"10.1016\/j.lfs.2024.123186_bb0755","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/nu14071341","article-title":"Pancreatic enzyme replacement therapy in cystic fibrosis","volume":"14","author":"Freswick","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2024.123186_bb0760","unstructured":"A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis|PLOS ONE n.d. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0212459 (accessed May 11, 2024)."},{"key":"10.1016\/j.lfs.2024.123186_bb0765","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13643-018-0757-y","article-title":"Dietary interventions for managing glucose abnormalities in cystic fibrosis: a systematic review protocol","volume":"7","author":"Birch","year":"2018","journal-title":"Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0770","first-page":"1","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0775","first-page":"10","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.123186_bb0780","first-page":"12","article-title":"On the corner of models and cure: gene editing in cystic fibrosis","author":"Ensinck","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123186_bb0785","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00439-021-02272-5","article-title":"Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application","volume":"141","author":"Kratzer","year":"2022","journal-title":"Hum. Genet."},{"key":"10.1016\/j.lfs.2024.123186_bb0800","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/genes11060619","article-title":"Molecular diagnosis and genetic counseling of cystic fibrosis and related disorders: new challenges","volume":"11","author":"Bienvenu","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.lfs.2024.123186_bb0805","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s10897-011-9363-z","article-title":"Shock, adjust, decide: reproductive decision making in cystic fibrosis (CF) carrier couples\u2014a qualitative study","volume":"20","author":"Myring","year":"2011","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.lfs.2024.123186_bb0810","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10897-013-9636-9","article-title":"Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of genetic counselors","volume":"23","author":"Langfelder-Schwind","year":"2014","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.lfs.2024.123186_bb0815","article-title":"Shared decision-making tool for self-management of home therapies for patients with cystic fibrosis","volume":"2","author":"Eckman","year":"2017","journal-title":"MDM Policy Pract."},{"key":"10.1016\/j.lfs.2024.123186_bb0820","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/thoraxjnl-2017-210858","article-title":"Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review","volume":"74","author":"Rowbotham","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2024.123186_bb0825","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069461","article-title":"Systematic review of shared decision-making interventions for people living with chronic respiratory diseases","volume":"13","author":"Barradell","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.lfs.2024.123186_bb0830","doi-asserted-by":"crossref","unstructured":"What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment? | BMJ Open Respiratory Research n.d. https:\/\/bmjopenrespres.bmj.com\/content\/7\/1\/e000601.abstract (accessed May 11, 2024).","DOI":"10.1136\/bmjresp-2020-000601"},{"key":"10.1016\/j.lfs.2024.123186_bb0835","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12890-023-02463-y","article-title":"How personality influences health outcomes and quality of life in adult patients with cystic fibrosis","volume":"23","author":"Niehammer","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0840","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/thx.53.9.727","article-title":"Quality of life in patients with cystic fibrosis and their parents: what is important besides disease severity?","volume":"53","author":"Staab","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2024.123186_bb0845","article-title":"Psychological interventions for individuals with cystic fibrosis and their families","author":"Goldbeck","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0850","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12890-021-01613-4","article-title":"Identifying specific needs in adult cystic fibrosis patients: a pilot study using a custom questionnaire","volume":"21","author":"Dury","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0855","article-title":"Psychological interventions for individuals with cystic fibrosis and their families","volume":"2014","author":"Goldbeck","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123186_bb0860","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40291-018-0372-6","article-title":"Innovative therapies for cystic fibrosis: the road from treatment to cure","volume":"23","author":"Cabrini","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0865","series-title":"Cystic Fibrosis: Heterogeneity and Personalized Treatment","author":"Wat","year":"2020"},{"key":"10.1016\/j.lfs.2024.123186_bb0870","first-page":"437","article-title":"Personalized medicine; a potential therapy for cystic fibrosis","volume":"9","author":"Ashraf","year":"2023","journal-title":"Adv. Life Sci."},{"key":"10.1016\/j.lfs.2024.123186_bb0875","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with Ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm. Ther."},{"key":"10.1016\/j.lfs.2024.123186_bb0880","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0885","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/life13061305","article-title":"Future comorbidities in an aging cystic fibrosis population","volume":"13","author":"Ticona","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.lfs.2024.123186_bb0890","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/jpm11050382","article-title":"The equitable implementation of cystic fibrosis personalized medicines in Canada","volume":"11","author":"Shemie","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.lfs.2024.123186_bb0895","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.lfs.2024.123186_bb0900","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00063198-199711000-00006","article-title":"Ethical considerations in the treatment of cystic fibrosis","volume":"3","author":"Tonelli","year":"1997","journal-title":"Curr. Opin. Pulm. Med."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:41:26Z","timestamp":1736185286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524007768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":176,"alternative-id":["S0024320524007768"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123186","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123186"}}